May 15, 2013 06:04PM ARIAD Announces Data Presentations and Webcast of Investor Briefing at the 2013 ASCO Annual Meeting
May 13, 2013 07:35AM ARIAD to Present at UBS Global Healthcare Conference
May 7, 2013 07:35AM ARIAD Reports First Quarter 2013 Financial Results and Development Progress
May 6, 2013 07:35AM ARIAD to Present at Bank of America Merrill Lynch Healthcare Conference
Apr 23, 2013 07:35AM ARIAD to Host Conference Call and Webcast Discussion of First Quarter 2013 Financial Results on May 7, 2013
Apr 10, 2013 08:00AM ARIAD Presents New Preclinical Data Showing AP26113 Inhibits Clinically Relevant Mutants of ALK and ROS1
Apr 9, 2013 08:00AM ARIAD Presents New Preclinical Data Showing Ponatinib Overcomes Resistant Mutations in KIT, an Oncogenic Driver of Gastrointestinal Stromal Tumors
Apr 8, 2013 07:35AM ARIAD Presents New Preclinical Data Showing Ponatinib is a Potent Inhibitor of RET and FGFR, Two Oncogenic Drivers of Non-Small Cell Lung Cancer
Apr 4, 2013 07:35AM ARIAD Provides Update on Important Progress Being Made in R&D and Commercial Initiatives
Apr 3, 2013 06:48PM ARIAD to Host Investor Conference Call Tomorrow, April 4th at 8:00 A.M. ET
Apr 2, 2013 07:35AM ARIAD Announces Support of Patients with Resistant or Intolerant CML Through Its Donation to Chronic Disease Fund
Mar 22, 2013 08:32AM ARIAD Announces That Iclusig™ (Ponatinib) Receives Positive CHMP Opinion for Approval in the European Union
Dec 6, 2010 09:02AM Ariad (ARIA) May Have Been Best at ASH Meeting